• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Historical and epidemiologic background of human premalignant breast disease.

作者信息

Page D L, Jensen R A, Simpson J F, Dupont W D

机构信息

Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.

出版信息

J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):341-9. doi: 10.1023/a:1009521726605.

DOI:10.1023/a:1009521726605
PMID:14973380
Abstract

Premalignant breast disease in humans is a concept that admits to a broad range of elements and possible determinants predicting the likelihood of developing breast cancer. Most of these elements are relative, such as the risk of breast cancer for women that is 130 times that of men and peaks at a younger age by about 10 years. Breast cancer is clearly a stochastic, multifactorial process that evolves over many years in which we must make predictions by likelihood. This review will present the most specially defined and reliably proven of these elements, highlighting anatomic and molecular factors.

摘要

相似文献

1
Historical and epidemiologic background of human premalignant breast disease.
J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):341-9. doi: 10.1023/a:1009521726605.
2
Anatomic markers of human premalignancy and risk of breast cancer.
Cancer. 1990 Sep 15;66(6 Suppl):1326-35. doi: 10.1002/1097-0142(19900915)66:14+<1326::aid-cncr2820661405>3.0.co;2-p.
3
High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer.在因乳腺癌遗传风险而接受预防性乳房切除的女性中,癌前病变的患病率较高。
J Clin Oncol. 2003 Jan 1;21(1):41-5. doi: 10.1200/JCO.2003.02.137.
4
Premalignant breast lesions: role for biological markers in predicting progression to cancer.乳腺癌前病变:生物标志物在预测癌症进展中的作用
Eur J Cancer. 1999 May;35(5):693-7. doi: 10.1016/s0959-8049(99)00026-x.
5
Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.与老年女性相比,年轻女性原发性对侧乳腺癌的相关年龄因素。
Breast Cancer Res Treat. 2019 Feb;173(3):657-665. doi: 10.1007/s10549-018-5031-4. Epub 2018 Oct 30.
6
Biological features of premalignant disease in the human breast.人类乳腺癌前病变的生物学特征。
J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):351-64. doi: 10.1023/a:1009573710675.
7
Premalignant conditions and markers of elevated risk in the breast and their management.
Surg Clin North Am. 1990 Aug;70(4):831-51. doi: 10.1016/s0039-6109(16)45184-4.
8
Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case-control study.50岁及以下女性血浆类胡萝卜素与乳腺癌前病变风险:一项巢式病例对照研究。
Breast Cancer Res Treat. 2017 Apr;162(3):571-580. doi: 10.1007/s10549-017-4152-5. Epub 2017 Feb 11.
9
Why babies do not want to nurse the premalignant breast side in breast-feeding mother? A possible sign of early diagnosis of breast cancer in younger women.为什么母乳喂养的母亲怀中的婴儿不愿吮吸患癌前乳房一侧的乳汁?这可能是年轻女性乳腺癌早期诊断的一个迹象。
J BUON. 2018 Mar-Apr;23(2):536.
10
Benign breast disease and breast cancer risk: morphology and beyond.良性乳腺疾病与乳腺癌风险:形态学及其他方面
Am J Surg Pathol. 2003 Jun;27(6):836-41. doi: 10.1097/00000478-200306000-00017.

引用本文的文献

1
Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies.早期乳腺癌前驱病变:分子与临床研究的经验教训
Breast Care (Basel). 2010 Aug;5(4):218-226. doi: 10.1159/000319624. Epub 2010 Aug 23.
2
Clinicopathologic characteristics and prognosis for molecular subtypes in low-grade breast carcinoma: comparison with grade one invasive ductal carcinoma-not otherwise specified.低级别乳腺癌的分子亚型的临床病理特征和预后:与一级非特指浸润性导管癌的比较。
Med Oncol. 2012 Dec;29(4):2556-64. doi: 10.1007/s12032-012-0174-3. Epub 2012 Feb 7.
3
Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions.

本文引用的文献

1
Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Reference Pathologists of the Canadian National Breast Screening Study.乳腺钼靶密度与良性乳腺疾病组织学类型的患病率和发病率。加拿大国家乳腺筛查研究的参考病理学家。
Eur J Cancer Prev. 2000 Feb;9(1):15-24. doi: 10.1097/00008469-200002000-00003.
2
Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.激素替代疗法对乳腺癌风险的影响:雌激素与雌激素加孕激素对比
J Natl Cancer Inst. 2000 Feb 16;92(4):328-32. doi: 10.1093/jnci/92.4.328.
3
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
自发性猫科动物乳腺上皮内病变作为人类雌激素受体和孕激素受体阴性乳腺病变的模型。
BMC Cancer. 2010 Apr 22;10:156. doi: 10.1186/1471-2407-10-156.
4
History of benign breast disease and risk of breast cancer among women in China: a case-control study.中国女性良性乳腺疾病史与乳腺癌风险:一项病例对照研究。
Cancer Causes Control. 2008 Oct;19(8):819-28. doi: 10.1007/s10552-008-9145-6. Epub 2008 Mar 18.
5
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.FHIT、PCNA和EGFR在乳腺良恶性病变中的表达
Br J Cancer. 2007 Jan 15;96(1):110-7. doi: 10.1038/sj.bjc.6603512. Epub 2006 Dec 12.
6
Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening.在全国乳腺钼靶筛查覆盖人群中,原位乳腺癌后患浸润性乳腺癌的风险。
Br J Cancer. 2005 Jan 17;92(1):162-6. doi: 10.1038/sj.bjc.6602250.
更年期雌激素及雌激素 - 孕激素替代疗法与乳腺癌风险
JAMA. 2000 Jan 26;283(4):485-91. doi: 10.1001/jama.283.4.485.
4
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer.良性乳腺疾病中的HER-2/neu基因扩增与后续患乳腺癌的风险
J Clin Oncol. 2000 Jan;18(2):267-74. doi: 10.1200/JCO.2000.18.2.267.
5
Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia.转化生长因子-β与乳腺上皮增生女性的乳腺癌风险
J Natl Cancer Inst. 1999 Dec 15;91(24):2096-101. doi: 10.1093/jnci/91.24.2096.
6
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.他莫昔芬治疗乳腺导管内癌:国家外科辅助乳腺和肠道项目B-24随机对照试验
Lancet. 1999 Jun 12;353(9169):1993-2000. doi: 10.1016/S0140-6736(99)05036-9.
7
Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group.可触及乳腺囊肿女性患乳腺癌的风险:一项前瞻性研究。爱丁堡乳腺研究小组。
Lancet. 1999 May 22;353(9166):1742-5. doi: 10.1016/s0140-6736(98)06408-3.
8
Ductal carcinoma in situ--the focus for prevention, screening, and breast conservation in breast cancer.导管原位癌——乳腺癌预防、筛查及保乳治疗的重点。
N Engl J Med. 1999 May 13;340(19):1499-500. doi: 10.1056/NEJM199905133401909.
9
The influence of margin width on local control of ductal carcinoma in situ of the breast.切缘宽度对乳腺导管原位癌局部控制的影响。
N Engl J Med. 1999 May 13;340(19):1455-61. doi: 10.1056/NEJM199905133401902.
10
Estrogen replacement therapy in women with a history of proliferative breast disease.有增生性乳腺疾病病史女性的雌激素替代疗法。
Cancer. 1999 Mar 15;85(6):1277-83. doi: 10.1002/(sici)1097-0142(19990315)85:6<1277::aid-cncr9>3.0.co;2-e.